Literature DB >> 20173495

Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?

Andres G Chiesa1, Michael T Deavers, Emanuela Veras, Elvio G Silva, David Gershenson, Anais Malpica.   

Abstract

At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed. We reviewed 33 cases of borderline OInMT, with either optimal or adequate sampling and with at least 5 years of follow-up, to investigate their behavior. Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively. The patients' age ranged from 16 to 89 years (mean 49 yr). Tumor size ranged from 8 to 39 cm (mean 20 cm). The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases. The patients were treated surgically as follows: cystectomy (1), unilateral oophorectomy or unilateral salpingo-oophorectomy with or without total abdominal hysterectomy (13), and bilateral salpingo-oophorectomy with or without total abdominal hysterectomy (19). Complete or partial staging was obtained in 26 patients. All of them had Federation of Gynecology and Obstetrics stage I disease. Thirty-one patients with a follow-up ranging from 5 to 18 years (mean 10 yr) had no recurrences. Two patients had recurrences 12 and 14 months after their initial surgery. The first patient underwent a left salpingo-oophorectomy and limited staging for a borderline OInMT adherent to the ileum and sigmoid. The tumor was incompletely removed and recurred in the pelvis 1 year later. It was again incompletely excised. Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status. She died of other causes 5 years later. The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT. Fourteen months later, she developed a recurrence in the residual ovary. She underwent a right salpingo-oophorectomy and total abdominal hysterectomy and has been without evidence of disease for 11 years. In this study of 33 Federation of Gynecology and Obstetrics stage I borderline OInMTs that were optimally or adequately sampled to exclude intraepithelial carcinoma, microinvasion, or invasive carcinoma, there were only 2 cases with recurrence, secondary to incomplete excision or cystectomy, and no deaths from disease. However, borderline OInMTs are usually large and heterogeneous, and the standard sampling protocol for them is not evidence based. As indicated by one of our consultation cases, there remains the potential for a sampling artifact in which a focus of carcinoma is missed. Caution dictates retaining the current nomenclature to ensure the follow-up of patients affected by this disease until uncertainty regarding the extent of sampling needed to exclude the presence of carcinoma is resolved.

Entities:  

Mesh:

Year:  2010        PMID: 20173495     DOI: 10.1097/PGP.0b013e3181bc2706

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  3 in total

Review 1.  Epithelial borderline ovarian tumor: Diagnosis and treatment strategy.

Authors:  Kimio Ushijima; Kouichiro Kawano; Naotake Tsuda; Shin Nishio; Atsumu Terada; Hiroyuki Kato; Kazuto Tasaki; Ken Matsukuma
Journal:  Obstet Gynecol Sci       Date:  2015-05-19

2.  Mucinous borderline ovarian tumors: pathological and prognostic study at Salah Azaiez Institute.

Authors:  Ghada Sahraoui; Asma Fitouri; Lamia Charfi; Maha Driss; Maher Slimane; Monia Hechiche; Karima Mrad; Raoudha Doghri
Journal:  Pan Afr Med J       Date:  2022-04-29

Review 3.  Mucinous tumors of the ovary: current thoughts on diagnosis and management.

Authors:  Jubilee Brown; Michael Frumovitz
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.